MLICM
ERNA icon

Metropolitan Life Insurance Company (MetLife)’s Eterna Therapeutics ERNA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1
Closed -$80.1K – 2800
2021
Q3 		$80.1K Hold
1
– – ﹤0.01% 2642
2021
Q2 		$149K Buy
+1
New +$144K ﹤0.01% 2368

Other funds holding ERNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ERNA Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Eterna Therapeutics (ERNA) in Q4 2021, closing a stake of 1 share — an estimated $80.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ERNA in Q2 2021 and held it in 2 quarters. The position peaked at $149K in Q2 2021. 47 funds tracked by Wall St. Rank hold ERNA as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Eterna Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1 Eterna Therapeutics share in Q4 2021, an estimated $80.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Eterna Therapeutics in Q2 2021 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Eterna Therapeutics position peaked at $149K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.